| TARGET | Novartis India Ltd, the BSE-listed commercial arm of Novartis in India |
|---|
| SELLER | Novartis AG, selling its entire 70.68% (1,74,50,680 shares) |
| BUYERS | WaveRise Investments 56.45% · ChrysCapital Fund X 10.32% · Two Infinity Partners 3.91% (Medical Dialogues; Business Today names five buyers, also including ChrysCapital X, LLC and OceanEdge Investments) |
| PRICE | About ₹1,446 Cr · WaveRise at ₹860.64 a share · Fund X and Two Infinity at ₹701.25 (Outlook Business; not confirmed elsewhere) |
| OPEN OFFER | 26% (64,19,608 shares) at ₹860.64, up to ₹552.49 Cr · letter of offer 1 Jun 2026 · market price ₹1,351.20 on 4 Jun |
| TENDERS | 10 shares by 19 Jun, 182 by 24 Jun · one source says 40 accepted (single source) |
| TARGET FINANCIALS | FY25 (March) revenue from operations ₹356.27 Cr · profit after tax ₹100.90 Cr |
| STATUS | Completion was expected in Q3 2026 and is not confirmed in the sources read |
| THE ACCESS POINT
Novartis India is listed on BSE and NSE and can be bought in the market. ChrysCapital's own funds are open only to qualified investors. |
|---|
Executive decision summary
| THE BOTTOM LINE | Novartis AG agreed on 19 and 20 February 2026 to sell its entire 70.68% of Novartis India to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners for about ₹1,446 crore, about US$159 million. The research brief for this note gave July 2026; every source read dates the agreement to February. The deal forced an open offer for 26% at ₹860.64 a share, which was only 3.6% above the 19 February close and well below the ₹1,351 market price seen in June, so almost nobody tendered: 182 shares by 24 June. The company is small, with FY25 profit of ₹100.90 crore and reported bank balances of several hundred crore (from a search snippet). The buyers say they will not delist. Completion was expected in the third quarter of 2026 and is not confirmed in the sources read. |
|---|
| WHICH INVESTOR | The deal fits a pharma-sector watcher IF you track multinational exits from Indian listed units and private equity taking control of legacy brands.
Wait IF you need the completion date, the final open-offer count or FY26 profit explained: none was confirmed. |
| COMFORT FIT | Carve-out = a multinational sells its local listed business but keeps its global research and other units.
Open offer = after a buyer takes control, it must offer to buy another 26% from public shareholders at a set price.
Legacy brands = older established medicines such as Voveran and Calcium Sandoz, steady but not fast-growing.
Tendering = a shareholder sells into the open offer. When the market price is higher, almost no one does. |
| THE RUPEIA NUMBER | ₹860.64. The price per share paid by WaveRise and offered to the public, against ₹1,351.20 in the market on 4 June 2026. |
1 CLAIM REGISTER: EVIDENCE GRADING
| Claim | Source | Grade | Rupeia assessment |
|---|
| Novartis AG sells entire 70.68% (1,74,50,680 shares) for about ₹1,446 Cr | Business Today; Medical Dialogues | B | Established |
| WaveRise 56.45%, Fund X 10.32%, Two Infinity 3.91% | Medical Dialogues | C | Established; single detailed source |
| Open offer 26% at ₹860.64, up to ₹552.49 Cr | Business Today; Medical Dialogues | B | Established |
| Fund X and Two Infinity paid ₹701.25 | Outlook Business only | D | Reconciles with the ₹1,446 Cr total, but needs the SPA filing |
| Agreement dated 19–20 Feb 2026; completion expected Q3 2026 | Business Today; Medical Dialogues | B | Established; completion not confirmed |
| Open-offer tenders: 10 to 182 shares; 40 accepted | Whalesbook; ScanX (40 accepted, single source) | D | Official acceptance filing not found |
| Q3 FY26 profit ₹525.6 Cr | Search snippet only | D | Unverified and unexplained |
2 THE DEAL AND HOW THE PRICE ADDS UP
| Item | Detail |
|---|
| Stake sold | 70.68%, 1,74,50,680 shares, the whole Novartis AG holding |
| Buyers | WaveRise Investments 56.45%; ChrysCapital Fund X 10.32%; Two Infinity Partners 3.91% |
| Other terms | Company to drop seller-group references from its name within 120 days of completion; non-recourse warranties; company to help with the open offer |
| Delisting | Acquirers say they do not intend to delist and will meet minimum public shareholding norms |
| Why Novartis sold | Strategic review since February 2024; focus on innovative medicines and a simpler global structure |
| Not sold | Novartis Healthcare Pvt Ltd (more than 9,000 staff, Hyderabad R&D) is not part of the sale |
| Calculation (Rupeia) | Result |
|---|
| Total shares in the company | 1,74,50,680 ÷ 70.68% ≈ 2.469 crore |
| WaveRise parcel | 56.45% × 2.469 crore ≈ 1.394 crore shares × ₹860.64 ≈ ₹1,199 Cr |
| Fund X and Two Infinity parcel | (10.32% + 3.91%) × 2.469 crore ≈ 0.351 crore shares × ₹701.25 ≈ ₹246 Cr |
| Total | ₹1,199 Cr + ₹246 Cr ≈ ₹1,445.9 Cr, matching the ₹1,445.89 Cr reported |
| Open offer check | 64,19,608 shares × ₹860.64 = ₹552.5 Cr, matching the maximum |
| Dollar rate implied | ₹1,446 Cr ÷ US$159m ≈ ₹91 per US$ |
| RUPEIA READ
The two prices that looked contradictory in the sources fit together. The part of the stake bought by WaveRise carried the open-offer price of ₹860.64 and the smaller parcels bought by Fund X and Two Infinity carried ₹701.25, and the total matches the reported ₹1,446 crore to within ₹1 crore. That supports the Outlook Business figure, although the SPA disclosure itself was not opened. |
|---|
3 THE OPEN OFFER: WHY NOBODY TENDERED
| Date | Fact | Source |
|---|
| 19 Feb 2026 | Close ₹830.45; offer price ₹860.64 is a 3.64% premium | Business Today |
| 20 Feb 2026 | Shares rose about 20% to the upper circuit, traded about ₹976 before the halt | Outlook Business |
| 1 Jun 2026 | Letter of offer dated | Whalesbook |
| 4 Jun 2026 | Market price ₹1,351.20 against the offer at ₹860.64 | Whalesbook |
| 19 Jun 2026 | 10 physical shares tendered, none in demat form | Whalesbook |
| 24 Jun 2026 | 182 physical shares tendered (BSE disclosure per search snippets) | Whalesbook; snippets |
| 10 Jul 2026 | 40 shares accepted from 182 tendered; acquirer holding 1,74,50,720 shares | ScanX; single source |
| Calculation (Rupeia) | Result |
|---|
| Market price against offer price, 4 Jun | ₹1,351.20 ÷ ₹860.64 − 1 = 57% above the offer |
| Tenders against the offer size | 182 ÷ 64,19,608 = 0.003% |
| Value of 100% at the offer price | 2.469 crore × ₹860.64 ≈ ₹2,125 Cr |
| Value of 100% at ₹1,351.20 | 2.469 crore × ₹1,351.20 ≈ ₹3,336 Cr |
| Offer price ÷ FY25 profit | ₹2,125 Cr ÷ ₹100.90 Cr ≈ 21x |
| RUPEIA READ
An open offer priced 57% below the market is not meant to be taken up, so public holders kept their shares and the acquirers ended with essentially their negotiated 70.68% plus a handful of shares. For ordinary shareholders the real change is that control moved to ChrysCapital, not that they had to decide. Free float stays close to 29%. |
|---|
4 WHAT THE COMPANY EARNS
| Measure | Value | Source quality |
|---|
| FY25 revenue from operations | ₹356.27 Cr | Business Today |
| FY25 total income | ₹398.23 Cr | Business Today |
| FY25 profit after tax | ₹100.90 Cr | Business Today |
| FY24 revenue and profit | ₹335 Cr and ₹85 Cr | Search snippet |
| Cash and bank balances | About ₹52.07 Cr cash plus ₹595.96 Cr other bank balances | Search snippet; layout inferred |
| Q3 FY26 revenue and profit | ₹411.8 Cr and ₹525.6 Cr | Search snippet; unexplained |
| Brands | Voveran, Calcium range, Methergine (sold with Dr Reddy's); transplant range including Simulect, Certican, Sandimmun, Neoral and Myfortic | Company and snippets |
| Calculation (Rupeia) | Result |
|---|
| FY25 profit margin on total income | ₹100.90 Cr ÷ ₹398.23 Cr = 25.3% |
| Revenue growth FY24 to FY25 | ₹356.27 Cr ÷ ₹335 Cr − 1 = 6.3% |
| Profit growth FY24 to FY25 | ₹100.90 Cr ÷ ₹85 Cr − 1 = 18.7% |
| Value at the offer price less reported cash (if the snippet is right) | ₹2,125 Cr − ₹648 Cr ≈ ₹1,477 Cr, about 14.6x FY25 profit |
The Q3 FY26 figure of ₹525.6 crore profit on ₹411.8 crore revenue would be five times the FY25 annual profit. It appears only in a search snippet and is unexplained, so it is not used in any calculation. It could reflect an exceptional gain, but the sources read do not say.
| RUPEIA READ
A 25% margin and a steady, brand-led portfolio explain the interest. A low growth rate of about 6% on revenue explains why the multiple is modest. The unexplained quarterly profit and the cash balance are the two items that would change the valuation most, and both need the annual report or exchange filings. |
|---|
5 THE BUYERS AND THE CARVE-OUT PATTERN
| Item | Detail |
|---|
| ChrysCapital Fund X | Final close US$2.2bn announced 5 Nov 2025, within six months of first close; described as the largest PE fund raised by an India-focused firm |
| ChrysCapital Fund IX | US$1.35bn, closed in 2022 |
| Firm record | More than US$5.5bn deployed across 110 portfolio companies; sectors consumer, healthcare, financial services, enterprise technology and industrial |
| People | Kunal Shroff (Managing Partner and CEO), Sanjay Kukreja (Partner and CIO) and Sudip Nandy (Managing Director and Operating Partner), from search snippets only |
| Pattern | Commentary frames the sale as separating legacy product portfolios from innovation R&D; analyst Salil Kallianpur: "This is not Novartis exiting India." |
| RUPEIA CALCULATION
Fund X at US$2.2bn is 2.2 ÷ 1.35 − 1 = 63% larger than Fund IX. The Novartis India deal of about US$159m is 159 ÷ 2,200 = 7.2% of Fund X, though part of the money came from WaveRise and Two Infinity, not from Fund X alone, so the Fund X share is smaller. |
|---|
| RUPEIA READ
A consortium structure, with WaveRise taking more than four-fifths of the stake, means the deal is not a pure Fund X purchase. Who is behind WaveRise and Two Infinity was not found. For an investor in ChrysCapital funds, the unknown is how much of the exposure sits in Fund X. |
|---|
6 RISKS, SCENARIOS AND CHECKLIST
| Risk | Evidence | Severity | Kill condition |
|---|
| Brand and distribution terms | No royalty or licence disclosure found; Dr Reddy's distribution for some brands | MEDIUM | Brand rights or licence fees surface |
| Earnings clarity | Q3 FY26 profit unexplained; cash figure from a snippet | MEDIUM | Profit proves one-off |
| Completion | Expected Q3 2026; not confirmed in sources read | LOW | Approvals delayed |
| Minority holders | Free float about 29%; open offer priced below market | MEDIUM | Float rules force a sell-down |
| Growth | Revenue growth about 6% in FY25 | MEDIUM | Portfolio erosion |
| Name change | Must drop seller-group references within 120 days of completion | LOW | Brand confusion |
| Scenario | What happens | Outcome |
|---|
| Bull | New owners add products and distribution; margin holds | Earnings grow above 6% |
| Base | Steady brands; cash returned over time | Stable earnings |
| Bear | Legacy brands erode and licensing costs appear | Profit falls |
| Investor class | Fit | Why |
|---|
| Long-term listed-market investor | PARTIAL | Cash-rich and profitable, but low growth and unexplained quarterly profit |
| ChrysCapital fund investor | INFORMATIONAL | Shows deal style: control of mature listed units |
| Short-term trader | LOW | Open offer is closed; float is thin |
Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. The open items are the completion date, the final open-offer count and the cash and Q3 profit figures.
7 KEY TERMS USED IN THIS REPORT
The terms below are used in this report. Each is explained in plain words.
| Term | Meaning |
|---|
| Open offer | A mandatory offer to public shareholders to buy a further 26% after control changes hands. |
| SPA | Share purchase agreement between buyer and seller. |
| Carve-out | A multinational sells a local unit while keeping its other businesses. |
| Minimum public shareholding | Rule that at least 25% of a listed company must be held by the public. |
| Upper circuit | The maximum a share may rise in a day under exchange rules. |
| Legacy brands | Older, established medicines with steady but slow-growing sales. |
Frequently asked questions
What did ChrysCapital buy?
A consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners agreed to buy Novartis AG's entire 70.68% of Novartis India for about ₹1,446 crore.
When was the deal agreed?
The agreement is dated 19 February 2026 and was announced on 20 February. Completion was expected in the third quarter of 2026 and is not confirmed in the sources read.
What was the open offer price?
₹860.64 a share for 26% of the company, up to ₹552.49 crore. The market price was ₹1,351.20 on 4 June, so very few shares were tendered.
Will Novartis India be delisted?
The acquirers say they do not intend to delist and will meet minimum public shareholding norms.
What does Novartis India earn?
FY25 revenue from operations was ₹356.27 crore and profit after tax ₹100.90 crore, per Business Today.
Does Novartis leave India?
No. Novartis Healthcare, with more than 9,000 staff and Hyderabad R&D, is not part of the sale.
Source log
Business Today: Novartis India promoter to sell entire 70.68% stake, triggering open offer at ₹860.64
Business Today: Why is Novartis selling its listed India commercial arm
Medical Dialogues: Novartis AG to exit India arm in ₹1,446 Cr deal
Outlook Business: Novartis India hits upper circuit as Swiss parent exits
Whalesbook: Novartis India open offer, ₹860.64 price lags market price of ₹1,351.20
Whalesbook: Novartis India open offer sees minimal tenders as of June 19
Entrackr: ChrysCapital closes US$2.2bn Fund X
| DISCLAIMER
This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. |
|---|